Expired activity
Please go to the PowerPak homepage and select a course.

The Impacts of Biosimilars on Pharmacists: Implications of the Evidence on Treatment Choices

This activity is provided by the Potomac Center for Medical Education and Rockpointe and is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Potomac Center for Medical Education Rockpointe


Edward Li, PharmD, MPH, BCOP
Associate Professor
University of New England College of Pharmacy
Portland, ME

Ali McBride, PharmD, MS, BCPS
Clinical Coordinator
University of Arizona Cancer Center
Tucson, AZ


Faculty Speaker/Steering Committee
The faculty/steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Edward Li, PharmD, MPH, BCOP: Honoraria: Pfizer, Merck, Sandoz; Speaker's Bureau: Hospira

Ali McBride, PharmD, MS, BCPS: Honoraria: Hospira, Sandoz; Speaker's Bureau: Hospira

Non-faculty Content Contributors
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Jeanelle Spencer, PhD; Carole Drexel, PhD, CHCP; Blair St. Amand; Jay Katz, CHCP; Laura Engles Horton; Lindsay Scott, PT, DPT, ATC: Nothing to disclose .


The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.50 hours (0.15 CEUs) of continuing education credit (program number 0418-9999-15-001-H01-P).


Credits: 1.50 hours (0.15 ceu)
Published: February 10, 2016
Expires: February 28, 2017
Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes


This activity is intended for pharmacists providing care for and/or making treatment decisions for cancer patients, nephrology patients, hematology patients, and patients with inflammatory rheumatologic, gastrointestinal, and dermatologic diseases.


During the period February 10, 2016 through February 28, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) review the full content of the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 80% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 80%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth (mm/dd) and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


In the next few years, a new generation of agents, the complex biosimilars, will be available in the United States (US) as biologics begin to lose their patents. Outside the US, experience with biosimilar products has grown in recent years. Current European Union (EU) biosimilars have been approved for multiple sclerosis; symptomatic anemia associated with chronic renal failure; symptomatic anemia in patients receiving chemotherapy for solid tumors, malignant lymphoma, or multiple myeloma; neutropenia; and autoimmune diseases (rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis).

In March 2015, the Food and Drug Administration (FDA) approved the first biosimilar drug for the US market. Several other agents are either undergoing FDA review or will undergo FDA review soon. The Impacts of Biosimilars on Pharmacists: Implications of the Evidence on Treatment Choices will review current evidence as it applies to oncology, hematology, rheumatology, gastroenterology, and dermatology patients. As biosimilars are incorporated into clinical practice, it will be necessary for healthcare professionals to have a thorough understanding of the clinical considerations associated with the use of these agents in their patients, so that the ultimate goal of increased patient accessibility to safe and effective treatments is achieved.


Upon completion of this activity, participants should be better able to:

  1. Identify the key differences between biosimilars, biologics, and generics as pertaining to production, regulatory requirements, and costs
  2. Evaluate the rationale for the use of biosimilars in patient care
  3. Assess the totality of the evidence of biosimilar agents for oncology, hematology, and inflammatory disease
  4. Review current United States (US) and out-of-US experiences with biosimilars


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure/Conflict of Interest Statement

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines set forth to providers by the Accreditation Council for Pharmacy Education (ACPE), the Accreditation Council for Continuing Medical Education (ACCME), and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

FDA Disclosure

The contents of some CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.